Acylated GLP-1 compounds
Protracted GLP-1 compounds and therapeutic uses thereof.
1. A compound of the structure
where the amino acid sequence is that of SEQ ID NO: 7.
2. A pharmaceutical composition comprising a compound of the structure
where the amino acid sequence is that of SEQ ID NO: 7, and a pharmaceutically acceptable excipient.
3. A method for treating type 2 diabetes in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a compound of the structure
where the amino acid sequence is that of SEQ ID NO: 7, and a pharmaceutically acceptable excipient.
4. A compound having the following name N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)peptide.
5. A pharmaceutical composition comprising a compound having the following name N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)peptide and a pharmaceutically acceptable excipient.
6. A method for treating type 2 diabetes in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a compound having the following name N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)peptide and a pharmaceutically acceptable excipient.